United States Patent 8,703,787: Ensartinib Patent Scope, Claims, Expiration and Generic Risk

US Patent 8,703,787 is a method-of-treatment patent covering the use of a defined class of substituted pyrimidine compounds against EML4-ALK-positive non-small cell lung cancer, including tumors resistant to crizotinib. The claims encompass ensartinib, the active ingredient in Ensacove, and related analogs and stereoisomers. The patent does not claim the compound as a composition of matter in the claims provided. Its enforceability therefore depends on proof of use for the claimed ALK-positive lung-cancer population, rather than merely making or selling the molecule.

The patent was issued to the original developer of the compound class and is part of the ensartinib patent family. Its reported expiration date is December 28, 2029, subject to any applicable patent-term adjustment or extension reflected in official records. Ensartinib received FDA approval on December 14, 2024, for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with crizotinib. FDA approval created five-year new chemical entity exclusivity that runs independently of the patent term and is expected to block an ANDA approval before December 2029, absent a successful regulatory challenge or forfeiture event. [1][2]

What drug does US Patent 8,703,787 protect?

The patent covers ensartinib and structurally related ALK inhibitors when used to treat EML4-ALK-positive NSCLC.

The compound identified in claim 7 is the principal commercial relevance:

5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine.

This compound is ensartinib, also known as X-396. Ensartinib is a small-molecule tyrosine kinase inhibitor designed to inhibit ALK, including ALK alterations associated with resistance to crizotinib. Ensacove is marketed by Xcovery, with Zai Lab involved in development and commercialization in specified territories. [2][3]

Patent identification

Item	Data
U.S. patent	US 8,703,787
Patent type	Method of treatment
Patent title	Pyrimidine compounds and methods of use thereof
Issue date	April 22, 2014
Relevant therapeutic target	EML4-ALK and ALK
Covered disease	EML4-ALK-positive NSCLC
Resistance population	NSCLC resistant to crizotinib
Commercial compound	Ensartinib
Brand	Ensacove
Reported patent expiration	December 28, 2029
FDA approval of ensartinib	December 14, 2024
FDA pathway	New drug application
Product type	Small molecule, oral ALK tyrosine kinase inhibitor

How broad are the claims in US Patent 8,703,787?

The claims have a layered structure. Claim 1 establishes a broad chemical genus tied to a highly specific therapeutic use. Claims 2 through 9 narrow the genus through resistance status, substituent identity, stereochemistry, selected compounds and patient type.

Claim 1: broad Markush method claim

Claim 1 requires all of the following:

EML4-ALK-positive NSCLC;
Administration to a cell or subject;
A compound of Formula (I), or a pharmaceutically acceptable salt;
The specified substituent definitions for R1 through R7;
Treatment of the cancer.

The claim is broad at the chemical level because it allows alternative substituents and ring systems. The major limitations are the disease and target limitations. A compound that falls within Formula (I) but is used for a non-ALK indication would not satisfy the claim as written.

The claim also reaches treatment of a cell, not only a human patient. That wording may support infringement theories involving ex vivo cell treatment, research use or certain laboratory applications, although commercial enforcement would normally focus on clinical administration.

Claim 2: crizotinib-resistant disease

Claim 2 narrows claim 1 to EML4-ALK-positive NSCLC that is resistant to crizotinib. This limitation is commercially important because it maps closely to the initial clinical positioning of ensartinib and the FDA-approved population.

The claim does not appear to require a particular molecular resistance mutation, disease stage, prior crizotinib duration or treatment line. A defendant could contest whether the patient population satisfies "resistant to crizotinib," particularly where treatment discontinuation resulted from intolerance, progression without documented resistance or another clinical reason.

Claims 3 through 5: substituent restrictions

These claims narrow the Formula (I) genus:

Claim	Limitation
3	R1 is chloro
4	R4 is isopropoxy
5	R5 and R6 form a ring containing -CH2-NR8-C(O)-

Claims 3 and 4 track the substitution pattern present in ensartinib. Claim 5 reaches a more constrained cyclic analog, including an isoindolinone-type structure.

Claims 6 through 8: named compounds

Claim 6 identifies six specific compounds or compound classes. It includes:

The piperidin-4-yl analog corresponding to ensartinib;
Piperidin-2-yl and piperidin-3-yl positional isomers;
R and S stereoisomers;
A fused heterocyclic isoindolinone analog.

Claims 7 and 8 further narrow claim 6 to two individual compounds. Claim 7 is the primary ensartinib claim. Claim 8 covers the named isoindolinone analog.

These claims are materially stronger against a product-specific challenge than the broad genus in claim 1 because they provide a direct structural route to infringement. They remain method claims, however. Manufacture, importation or sale of the compound alone does not necessarily infringe claim 7 without the required treatment use or inducement theory.

Claim 9: human or animal treatment

Claim 9 clarifies that the subject may be a human or animal. For the commercial product, human treatment is the relevant application. The animal language may have research and veterinary implications but does not expand the approved human indication.

What formulations are protected by US Patent 8,703,787?

The claims provided do not claim a tablet, capsule, dosage form, excipient system, salt form, polymorph, particle-size distribution, coating, release profile or manufacturing process.

The patent protects use of the claimed compounds, including pharmaceutically acceptable salts, in the specified cancer setting. It does not, on the face of these claims, create a standalone formulation barrier for an ensartinib tablet.

This distinction matters for generic entry. A generic applicant could potentially develop a formulation that differs from the branded product while still confronting the method claims if its labeling directs use in EML4-ALK-positive NSCLC or crizotinib-resistant disease.

Formulation and pharmaceutical-composition risk

The key formulation questions are separate from the claim text:

Whether other U.S. patents claim the marketed salt or solid form;
Whether any patent claims the tablet composition or manufacturing process;
Whether those patents are listed in the FDA Orange Book;
Whether the FDA-approved label contains protected use language;
Whether a generic applicant can use a section viii statement to omit the patented indication.

US 8,703,787 should therefore be treated as a use-patent asset, not as the complete ensartinib formulation estate.

When does ensartinib lose patent and regulatory exclusivity?

Ensartinib faces two separate exclusivity clocks.

Protection	Expected end date	Practical effect
US 8,703,787 patent term	December 28, 2029	May restrict covered treatment methods until expiration
FDA five-year NCE exclusivity	December 14, 2029	Generally prevents submission of an ANDA or 505(b)(2) application for the same active moiety during the exclusivity period
FDA approval anniversary	December 14, 2029	Earliest ordinary NCE-related approval date, subject to statutory rules
Patent expiration after NCE period	December 28, 2029	Leaves a short residual patent period based on the reported expiration date

The NCE period is particularly significant because it largely overlaps with the 8,703,787 patent term. A Paragraph IV certification may be submitted before patent expiration, but the patent challenge would not ordinarily produce an approved generic before the NCE exclusivity period ends.

The patent term could be affected by patent-term adjustment, patent-term extension, terminal disclaimers or other USPTO records. The operative date for launch analysis should be confirmed against the current patent and Orange Book records. [1][4]

What is the Orange Book status of ensartinib?

Ensacove is an FDA-approved small-molecule prescription drug. Its Orange Book position should be evaluated separately from the patent document because FDA listing determines whether an ANDA applicant must make a Paragraph IV certification or may use another certification pathway.

The relevant regulatory elements are:

Approved NDA: Ensacove;
Active ingredient: ensartinib;
Sponsor: Xcovery;
Indication: ALK-positive locally advanced or metastatic NSCLC after crizotinib;
Regulatory exclusivity: five-year NCE exclusivity;
Patent issue: whether US 8,703,787 and any continuation, formulation or method-of-use patents are listed against the NDA.

A method-of-use patent can be listed in the Orange Book if it claims an approved method of using the drug. If listed, an ANDA applicant must address the patent through a Paragraph IV certification, a section viii statement that omits the protected use, or another legally available certification. [4]

Are there Paragraph IV challenges to US Patent 8,703,787?

No publicly reported Paragraph IV litigation involving US 8,703,787 was identified in the materials available for this analysis.

The absence of public litigation does not establish that no certification has been submitted. Paragraph IV notices can precede publicly visible litigation, and litigation may be filed after receipt of a notice. A Paragraph IV certification would create a 45-day period for the patent owner or NDA holder to file suit and could trigger a 30-month stay of ANDA approval under the Hatch-Waxman framework. [5]

For ensartinib, the commercial timing reduces immediate Paragraph IV pressure because the product was approved in late 2024 and retains NCE exclusivity through December 2029. The more likely challenge window is before or around the end of NCE exclusivity, when a generic applicant seeks approval for a launch after regulatory exclusivity but before or shortly after the reported patent expiration.

What generic launch scenarios exist for ensartinib?

Scenario 1: no early challenge

A generic applicant waits until the NCE period is close to expiration, files with a Paragraph IV certification or section viii statement, and launches after regulatory exclusivity ends if the listed patent does not block approval.

This is the lowest-litigation scenario but may leave the applicant exposed to a patent suit filed near the end of the exclusivity period.

Scenario 2: Paragraph IV challenge to the method patent

An ANDA applicant argues that the patent is invalid, not infringed or unenforceable. Potential arguments could include:

Lack of written description across the breadth of the Markush genus;
Enablement concerns for the full scope of Formula (I);
Obviousness based on earlier ALK inhibitors and substituted pyrimidines;
Failure to prove the claimed clinical method;
Noninfringement based on an omitted indication;
Lack of induced infringement where the generic label does not encourage the patented use.

The named-compound claims create a more direct infringement risk than the broad genus claim. A challenger would likely focus on validity of claim 7 and any related listed claims rather than attack only the breadth of claim 1.

Scenario 3: skinny-label launch

If the listed patent covers only a specific use, a generic applicant may seek approval for nonprotected uses while carving out the patented indication. This strategy depends on the exact Orange Book use code and FDA-approved labeling.

For ensartinib, a skinny-label strategy could be difficult if the approved indication substantially overlaps the patented crizotinib-resistant EML4-ALK-positive population. The regulatory feasibility would depend on whether a meaningful noninfringing indication remains.

Scenario 4: settlement and delayed entry

A patent owner and generic applicant could resolve litigation through a settlement providing a date-certain launch. Any agreement involving a potential generic entrant would be subject to federal antitrust review and FTC reporting requirements under applicable law. No public settlement concerning US 8,703,787 was identified in the available record.

How strong is the patent estate for ensartinib?

US 8,703,787 is strategically valuable but narrower than a composition-of-matter patent.

Strengths

Claim 7 identifies the commercial compound directly.
Claim 2 targets crizotinib-resistant EML4-ALK-positive NSCLC, the principal initial treatment population.
The claimed use aligns closely with the FDA-approved indication.
The patent term extends beyond the five-year NCE exclusivity period on the reported dates.
Claim 6 provides fallback coverage for related analogs and stereoisomers.

Vulnerabilities

The claims supplied are method claims rather than product-by-process or composition claims.
Infringement depends on the use of the product, labeling, prescribing behavior or inducement evidence.
A generic may attempt an indication carve-out.
The broad genus in claim 1 may face written-description, enablement or obviousness scrutiny.
The value of claims covering analogs is limited if those analogs are not commercially used or listed in the approved product.

The estate is stronger for branded-label protection than for absolute control over manufacture and sale of ensartinib. A composition patent covering the active ingredient, salt, polymorph or formulation would materially improve the barrier. The relevant business question is therefore whether additional continuation, formulation or process patents supplement US 8,703,787.

Which companies compete with ensartinib?

Ensartinib competes in the ALK-positive NSCLC market with multiple approved ALK inhibitors.

Drug	Active ingredient	Company	Principal competitive position
Xalkori	Crizotinib	Pfizer	Earlier-generation ALK inhibitor and comparator therapy
Zykadia	Ceritinib	Novartis	Second-generation ALK inhibitor
Alecensa	Alectinib	Roche	Major first-line ALK therapy
Alunbrig	Brigatinib	Takeda	First-line and later-line ALK therapy
Lorbrena	Lorlatinib	Pfizer	Potent CNS-active ALK inhibitor
Augtyro	Repotrectinib	Bristol Myers Squibb	Next-generation targeted therapy for ROS1 and ALK-related settings
Ensacove	Ensartinib	Xcovery/Zai Lab	ALK-positive NSCLC after crizotinib under the initial FDA indication

The competitive landscape affects patent value. Ensartinib's commercial opportunity is shaped by treatment sequencing, central nervous system activity, resistance mutation coverage and physician preference. A patent covering post-crizotinib use may have high clinical relevance even though first-line competition is controlled by broader labels for alectinib, brigatinib and lorlatinib. [2][6]

What patent litigation affects ensartinib?

No publicly reported U.S. patent litigation specific to US 8,703,787 was identified in the available record.

There is no indication in the supplied information of:

A filed Hatch-Waxman complaint;
A 30-month stay;
A final judgment on validity or infringement;
A Paragraph IV settlement;
An authorized generic agreement;
A biosimilar dispute.

Because ensartinib is a small molecule, biosimilar litigation is not the relevant pathway. Any follow-on product would normally proceed through the ANDA pathway under section 505(j), or potentially a 505(b)(2) pathway for a different formulation, salt or delivery system. [5]

What manufacturing and geographic barriers apply?

US 8,703,787 does not claim a manufacturing process in the claims provided. It therefore may not prevent a third party from producing ensartinib through a different synthetic route, assuming no separate process, intermediate, salt or solid-form patent applies.

Geographically, the U.S. patent is enforceable only in the United States. International protection would depend on the corresponding national-phase patents in Europe, China, Japan, South Korea and other jurisdictions. The commercial estate should be mapped separately by country because:

Patent grant and expiration dates may differ;
Some countries may have supplementary protection certificates;
Patent claims may differ between jurisdictions;
Regulatory exclusivity periods are not uniform;
Litigation and compulsory-license rules vary.

A U.S. launch analysis should include importation risk. Importing an infringing product for use in the patented method can create liability even if manufacture occurs outside the United States, while process patents may create separate customs and ITC issues.

What is the revenue exposure from US 8,703,787?

The patent protects an important segment of ensartinib's addressable market but does not automatically protect every sale of the drug.

Revenue exposure is highest where:

The label expressly identifies crizotinib-resistant ALK-positive NSCLC;
Physicians prescribe the drug for that population;
The Orange Book use code tracks the approved indication;
A generic cannot omit the protected use without losing commercially meaningful demand;
No noninfringing label pathway is available.

Revenue exposure is lower where:

The generic label omits the patented indication;
Prescribing shifts to first-line use not covered by the claim;
Other ALK inhibitors control the relevant line of therapy;
The patent is invalidated or narrowly construed;
Separate patents expire earlier or are not listed.

The key commercial date is late 2029. A generic launch immediately after NCE exclusivity would depend on patent strategy, litigation outcome and the presence of other listed patents. If 8,703,787 is the principal remaining barrier, a successful challenge could create entry near December 2029. If other patents cover formulation, salt, polymorph or additional approved uses, effective exclusivity could extend beyond that date.

Key Takeaways

US 8,703,787 is a method-of-treatment patent for Formula (I) ALK inhibitors in EML4-ALK-positive NSCLC.
Claim 7 directly covers ensartinib, the active ingredient in Ensacove.
Claim 2 specifically targets crizotinib-resistant disease.
The patent does not, based on the supplied claims, independently claim ensartinib as a composition or a particular tablet formulation.
The reported patent expiration date is December 28, 2029.
Ensartinib's FDA five-year NCE exclusivity is expected to run through December 14, 2029.
A generic applicant would likely evaluate Paragraph IV, section viii and 505(b)(2) strategies.
No publicly reported Paragraph IV litigation or settlement concerning US 8,703,787 was identified in the available record.
Biosimilar risk is not applicable because ensartinib is a small molecule.
The decisive launch question is whether additional Orange Book-listed patents cover the active ingredient, formulation, solid form, manufacturing process or broader approved uses.

FAQs

Does US 8,703,787 cover ensartinib itself?

It covers the use of ensartinib in the claimed EML4-ALK-positive NSCLC treatment method. The claims provided do not constitute a standalone composition-of-matter claim.

Can a generic sell ensartinib before December 2029?

FDA NCE exclusivity is expected to prevent ordinary ANDA approval before December 14, 2029. Patent litigation could create a separate barrier through the reported December 28, 2029 patent expiration date.

Is claim 7 stronger than claim 1?

Yes. Claim 7 identifies a specific compound corresponding to ensartinib, while claim 1 covers a broader Markush genus. Claim 7 is narrower but provides a more direct infringement theory.

Could a generic use a skinny label to avoid the patent?

Potentially. The feasibility depends on the Orange Book use code, the exact approved labeling and whether a commercially viable noninfringing indication remains after carving out crizotinib-resistant EML4-ALK-positive NSCLC.

Does ensartinib have biosimilar competition?

No. Ensartinib is a chemically synthesized small molecule. Follow-on competition would generally involve an ANDA or, in some circumstances, a 505(b)(2) application rather than a biosimilar application.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,703,787, Pyrimidine compounds and methods of use thereof.
U.S. Food and Drug Administration. (2024). Ensacove (ensartinib) prescribing information.
Zai Lab Limited. (2024). Ensacove approved by the U.S. Food and Drug Administration for ALK-positive locally advanced or metastatic non-small cell lung cancer.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certification requirements.
National Comprehensive Cancer Network. (2025). NCCN clinical practice guidelines in oncology: Non-small cell lung cancer.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)	⤷ Start Trial
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	February 02, 2012	PCT Application Number:	PCT/US2012/023669
PCT Publication Date:	August 09, 2012	PCT Publication Number:	WO2012/106540

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012212142	⤷ Start Trial
Brazil	112013019643	⤷ Start Trial
Canada	2824092	⤷ Start Trial
China	103458881	⤷ Start Trial
Cyprus	1116662	⤷ Start Trial
Denmark	2670401	⤷ Start Trial
Eurasian Patent Organization	023404	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,703,787